Safety and Tolerability of Donepezil at Doses up to 20 mg/dayResults from a Pilot Study in Patients with Alzheimer’s Disease

被引：0
|
作者：
Rachelle S. Doody
Jody Corey-Bloom
Richard Zhang
Honglan Li
John Ieni
Rachel Schindler
机构：
[1] Baylor College of Medicine,Alzheimer’s Disease and Memory Disorders Center
[2] UCSD School of Medicine,Department of Neurosciences
[3] Pfizer Inc.,undefined
[4] Eisai Inc.,undefined
来源：
Drugs & Aging | 2008年 / 25卷
关键词：
Rivastigmine; Galantamine; Last Observation Carry Forward; Psychometric Measure; Adverse Event Monitoring;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Background: Donepezil is licensed for the treatment of mild-to-moderate Alzheimer’s disease (AD) at doses of 5–10 mg/day and has recently been approved in the US for severe AD. Multiple studies have suggested that donepezil 10 mg/day provides additional cognitive and functional benefits over the 5 mg/day dose. Higher doses of donepezil, if safe and well tolerated, might provide further benefits for patients with AD.
引用
下载
收藏
页码：163 / 174
页数：11
相关论文
共 50 条
  • [21] SWAP: the safety and tolerability of switching oral donepezil to rivastigmine patch in Alzheimer's disease (AD)
    Eagle, G.
    Alva, G.
    Farlow, M.
    Sadowsky, C.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2008, 56 (04) : S77 - S77
  • [22] SWAP: Safety and tolerability of switching oral donepezil to rivastigmine patch in Alzheimer's disease (AD)
    Alva, Gustavo
    Farlow, Martin
    Sadowsky, Carl
    Brannan, Stephen
    ANNALS OF NEUROLOGY, 2008, 64 : S39 - S40
  • [23] A Combination Therapy of Donepezil and Cilostazol for Patients With Moderate Alzheimer Disease: Pilot Follow-Up Study
    Arai, Heii
    AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2009, 17 (04): : 353 - 354
  • [24] Safety, Tolerability, and Pharmacokinetics of Crenezumab in Patients with Mild-to-Moderate Alzheimer's Disease Treated with Escalating Doses for up to 133 Weeks
    Guthrie, Heather
    Honig, Lawrence S.
    Lin, Helen
    Sink, Kaycee M.
    Blondeau, Kathleen
    Quartino, Angelica
    Dolton, Michael
    Carrasco-Triguero, Montserrat
    Lian, Qinshu
    Bittner, Tobias
    Clayton, David
    Smith, Jillian
    Ostrowitzki, Susanne
    JOURNAL OF ALZHEIMERS DISEASE, 2020, 76 (03) : 967 - 979
  • [25] Safety and Tolerability of Donepezil, Rivastigmine and Galantamine for Patients with Alzheimer's Disease: Systematic Review of the 'Real-World' Evidence
    Lockhart, I. A.
    Mitchell, S. A.
    Kelly, S.
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2009, 28 (05) : 389 - 403
  • [26] Effects of donepezil HCL on sleep and cognitive functioning in Alzheimer's Disease patients: A pilot study
    Riggs, RL
    Arnedt, JT
    Aloia, MS
    SLEEP, 2002, 25 : A495 - A496
  • [27] Donepezil versus rivastigmine tolerability study in dementia with Lewy bodies and Alzheimer's disease
    Magierski, R.
    Sobow, T.
    Kloszewska, I.
    PARKINSONISM & RELATED DISORDERS, 2007, 13 : S62 - S62
  • [28] The effect of donepezil on dementia in Parkinson's disease and Alzheimer's disease.: A pilot study
    Rektorová, I
    CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE, 2004, 67 (05) : 359 - +
  • [29] Effects of memantine in patients with moderate Alzheimer's disease receiving stable doses of donepezil
    Molinuevo, J. L.
    Lemming, O.
    Wilkinson, D.
    EUROPEAN JOURNAL OF NEUROLOGY, 2012, 19 : 470 - 470
  • [30] Donepezil in Alzheimer's disease patients: Integrated safety results from the clinical trial program
    Ieni, JR
    Pratt, RD
    Perdomo, CA
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 1999, 47 (09) : S63 - S63
12345